VICTORIA, May 6, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a
provider of best-in-class therapeutic antibody discovery
capabilities for the global industry, today announced its
laboratory in Victoria, BC, has
leased a high throughput, label-free Octet HTX biosensor from
FortéBio. This analytical tool addresses ImmunoPrecise's need for
increased speed and sample throughput when characterizing large
panels of therapeutic antibody candidates.
The Octet HTX offers dramatic time savings for researchers
studying the binding interactions of hundreds of drug candidates by
producing high quality data supported with analysis tools allowing
data-driven decisions to be made with confidence. It is especially
useful in early-stage screening to guide the library-to-leads
triage and cut time and costs.
"The need for higher analytical throughput is a central theme
within our pharma and biopharmaceutical customers," noted Yasmina
Abdiche, Chief Scientific Officer at ImmunoPrecise. "We believe
that the HTX system's throughput, versatility, reliability and ease
of use will accelerate our discovery efforts towards identifying
clinically-ready leads."
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
Contract Research Organization offering species agnostic,
multi-format, characterized and engineered, human monoclonal
antibodies, on an abbreviated timeframe, for its pharmaceutical
clients. For further information, visit
www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the previous quarter ended January 31, 2020 which can be accessed at
www.sedar.com. The "forward-looking statements" contained
herein speak only as of the date of this press release and, unless
required by applicable law, ImmunoPrecise undertakes no obligation
to publicly update or revise such information, whether as a result
of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.